In August 2024, her treatment was changed to fam-trastuzumab-deruxtecan (T-DXd) 5.4 mg/kg day 1 of a 21-day cycle, as her tumor was HER2 3+, and this drug received recent FDA approval for HER2 3+ tumors. Here, ERBB2 is linked to neoplasm.